May 13, 2020
How the COVID-19 outbreak could provide synbio’s breakout moment
A globally disruptive event such as the COVID-19 pandemic opens the door to new approaches and accelerates trends already in motion. We also urgently need a vaccine and treatments for COVID-19. As the global health care community mobilizes to this end, synthetic biology (synbio) companies are making a splash with their quick progress so far compared to traditional approaches. The spotlight will be on synthetic biology if it ends the pandemic and identifies viral threats in crowded spaces. An EY article provides details.